Richard Glickman
Vorsitzender bei ENGENE HOLDINGS INC.
Vermögen: 647 966 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Anthony Cheung | M | 53 |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 1 Jahre |
| Michael Martin | M | 52 | 31 Jahre | |
| Jason Hanson | M | 55 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 6 Jahre |
| Robert Foster | M | 65 | 31 Jahre | |
| Gerry Brunk | M | 55 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada.
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 22 Jahre |
| Alexander Nichols | M | 38 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 2 Jahre |
| Peter van der Velden | M | 62 |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 19 Jahre |
| James Helliwell | M | - | 12 Jahre | |
| Bruce Cousins | M | 63 |
Aspreva Pharmaceuticals Corp.
 Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | 8 Jahre |
| Erich Mohr | M | 70 |
MedGenesis Therapeutix, Inc.
 MedGenesis Therapeutix, Inc. Medical SpecialtiesHealth Technology MedGenesis Therapeutix, Inc. provides diagnostic product services. The private company is based in Victoria, Canada. The Canadian company was founded by Erich Mohr, Howard J. Federoff. Erich Mohr has been the CEO since incorporation. | 18 Jahre |
| Benjamin Rovinski | M | 67 |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 7 Jahre |
| David Parkinson | M | 73 | 9 Jahre | |
| Peter Greenleaf | M | 54 | 5 Jahre | |
| Daniel Billen | M | 70 | 5 Jahre | |
| Stephen Robertson | M | 42 | 10 Jahre | |
| lee Giguere | M | 43 | - | |
| Philip Kantoff | M | 69 | 2 Jahre | |
| Daniel Hetu | M | - |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 19 Jahre |
| Ann Thorell | F | 56 | 5 Jahre | |
| Jacki Jenuth | M | - |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 23 Jahre |
| Timothy J. Keiffer | M | - |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 25 Jahre |
| Franklin Berger | M | 74 | 9 Jahre | |
| Vik Peck | F | - | - | |
| Lauren Merendino | F | 49 | 1 Jahre | |
| Lota Zoth | F | 64 | 1 Jahre | |
| Sanford Zweifach | M | 68 | 5 Jahre | |
| Gary Sollis | M | 69 | 12 Jahre | |
| John Montalbano | M | 59 | 11 Jahre | |
| Simon Pimstone | M | 56 | 11 Jahre | |
| Alex Martin Martin | M | 55 | 5 Jahre | |
| Scott Requadt | M | 56 | 8 Jahre | |
| David Jaynee | M | 67 | 9 Jahre | |
| Amanda Malone | M | - | 12 Jahre | |
| Lu Han | M | - |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 4 Jahre |
| Ash Bassett | M | - | - | |
| James Sullivan | M | 45 | 1 Jahre | |
| Nikhil Thatte | M | - |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 5 Jahre |
| Michael Wilmink | M | - | 11 Jahre | |
| Suman Rao | F | - |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 3 Jahre |
| Baye Galligan | M | - |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 7 Jahre |
| Murray Webb | M | - | 7 Jahre | |
| Michael Leung | M | - |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 2 Jahre |
| Dahlia Abbott | M | - |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | - |
| Marco Boorsma | M | 49 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | - |
| Theodore Witek | M | 67 |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | - |
| H. Norton | M | 63 |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 8 Jahre |
| Armin M. Kessler | M | 85 |
MedGenesis Therapeutix, Inc.
MedGenesis Therapeutix, Inc. Medical SpecialtiesHealth Technology MedGenesis Therapeutix, Inc. provides diagnostic product services. The private company is based in Victoria, Canada. The Canadian company was founded by Erich Mohr, Howard J. Federoff. Erich Mohr has been the CEO since incorporation. | - |
| Colin R. Mallet | M | 80 |
MedGenesis Therapeutix, Inc.
MedGenesis Therapeutix, Inc. Medical SpecialtiesHealth Technology MedGenesis Therapeutix, Inc. provides diagnostic product services. The private company is based in Victoria, Canada. The Canadian company was founded by Erich Mohr, Howard J. Federoff. Erich Mohr has been the CEO since incorporation. | - |
| Paul Geyer | M | 61 | 11 Jahre | |
| Brian Underdown | M | 83 |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | - |
| Ryan Daws | M | 50 | 1 Jahre | |
| David Wood | M | 66 | 11 Jahre | |
| Paul Brennan | M | - | 2 Jahre | |
| Steven Gannon | M | 62 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 7 Jahre |
| Adam Peeler | M | - | - | |
| Peter Virsik | M | - | 8 Jahre | |
| Dennis Langer | M | 73 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 9 Jahre |
| Vasco Larcina | M | 59 |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | - |
| Mark Kowalski | M | 69 | 1 Jahre | |
| Alessandra Cesano | M | 63 | 5 Jahre | |
| Andrei Vladimirovich Petrov | M | 50 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 9 Jahre |
| David Novak | M | - |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | 2 Jahre |
| Jasper Bos | M | 49 | 1 Jahre | |
| Richard Bryce | M | 66 | 1 Jahre | |
| Sue Evans | F | - | 10 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Charles Rowland | M | 65 | 3 Jahre | |
| Robert W. Rieder | M | 78 | 6 Jahre | |
| George Milne | M | 80 |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | 10 Jahre |
| Raymond J. Andersen | M | 76 | 10 Jahre | |
| Michael Hayden | M | 72 |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | 9 Jahre |
| Stephen W. Zaruby | M | 61 | 3 Jahre | |
| Eric Adams | M | 61 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 9 Jahre |
| Noel F. Hall | M | - |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | 7 Jahre |
| R. MacKay-Dunn | M | 73 |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada.
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 7 Jahre |
| Peter Wijngaard | M | 61 | - | |
| Vassiliki Economides | F | 44 | 3 Jahre | |
| Larry Mandt | M | - |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | 9 Jahre |
| Ha-Cheol Kim | M | 61 | - | |
| Erik Eglite | M | - | 3 Jahre | |
| Eric Hsu | M | - |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 16 Jahre |
| Hyuek Joon Lee | M | 57 | 4 Jahre | |
| Simrat Randhawa | M | 56 | 5 Jahre | |
| Alexander Rothwell | M | - | 4 Jahre | |
| Robert B. Huizinga | M | 59 | 20 Jahre | |
| Donald W. Wyatt | M | 57 | - | |
| Joseph Hagan | M | 55 | 5 Jahre | |
| Dennis Bourgeault | M | 66 | 22 Jahre | |
| Gregory Ayers | M | - | 2 Jahre | |
| Jeff Randall | M | 80 | 3 Jahre | |
| Kurt von Emster | M | 56 | 1 Jahre | |
| Daniel Park | M | - | - | |
| Hugo Beekman | M | - | - | |
| Paul Cossum | M | 71 | 3 Jahre | |
| Alexandre Grassin | M | 46 | - | |
| Oreola Donini | M | 52 | 1 Jahre | |
| Andrew Dunlop | M | 52 |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | 3 Jahre |
| Otello Stampacchia | M | 55 | 1 Jahre | |
| Frank Perabo | M | 59 | 4 Jahre | |
| Scott Daniel Cormack | M | 59 | 2 Jahre | |
| Ari Brettman | M | 42 | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Kanada | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Richard Glickman
- Persönliches Netzwerk
